Pfizer ( (PFE) ) has been popular among investors this week. Here is a recap of the key news on this stock.
Pfizer (PFE) has been the focus of several analyst reports recently, with mixed ratings reflecting cautious optimism about the company’s future. Asad Haider from Goldman Sachs maintained a ‘Hold’ rating with a price target of $25.00, while Cantor Fitzgerald initiated coverage with a similar ‘Hold’ rating and a $24.00 price target. Despite these conservative ratings, the consensus among analysts is a ‘Moderate Buy’, with an average price target of $28.36, suggesting a potential upside of nearly 29% from current levels.
The company’s shares recently closed at $22.04, and its market cap stands at $125 billion with a P/E ratio of 15.64. While Pfizer faces challenges such as competitive pressures and anticipated losses of exclusivity, analysts believe that the company’s strategic adjustments to its cost base and margins could help navigate these hurdles. However, Pfizer’s recent decision to halt the development of its oral obesity drug due to safety concerns has left it trailing behind competitors like Eli Lilly in the obesity treatment market.